Ab&B Bio Tech Co Ltd JS ROA

Mitä Ab&B Bio Tech Co Ltd JS tekee? Ab&B Bio Tech Co Ltd JS generates revenue through the research, development, manufacturing, and commercialization of vaccines. The company's core products include the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, alongside 11 other vaccine candidates. It primarily serves the domestic market in China, focusing on vaccine solutions for public health needs. The company's business model centers on bringing its vaccine pipeline to market through domestic sales and commercialization efforts. The firm operates within the biotechnology industry, specifically targeting vaccine development and production. Its product portfolio consists of two core vaccines and 11 additional candidates, all aimed at addressing infectious disease prevention. Ab&B Bio Tech Co Ltd JS leverages its domestic market presence to sell these products, with no mention of international sales or partnerships in the business description. The company's revenue streams derive from the commercialization of its vaccine pipeline, including the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate. It focuses on the Chinese domestic market for product distribution and sales, with no indication of export activities or foreign market engagement. Ab&B Bio Tech Co Ltd JS's business model emphasizes in-country development and sales of vaccines to meet local healthcare demands. Ab&B Bio Tech Co Ltd JS on yksi Eurpooliin suosituimmista yhtiöistä.